JAK2 V617F and MPL W515L/K Mutations in Korean Patients with Essential Thrombocythemia
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
JAK2 V617F and MPL W515L/K mutations have been reported in approximately 50% and 5% of the patients with essential thrombocythemia (ET), respectively. We investigated the frequency of MPL W515L/K mutations in a series of consecutive patients with ET and post-essential thrombocythemia myelofibrosis (post-ET MF). The study subjects were 63 patients diagnosed either with ET (N=59) or post-ET MF (N=4) at our institution between June 2006 and February 2010. Among them, 35 (55.6%) had the JAK2 V617F mutation. MPL W515L/K mutations were detected by direct sequencing analyses of exon 10, and 2 patients were found to harbor the following MPL mutations: W515L in 1 patient with ET and W515K in 1 patient with post-ET MF. Neither of the patients had the JAK2 V617F mutation. The frequencies of the MPL W515L/K and JAK2 V617F-negative mutations in our subjects with ET/post-ET MF were 3.2% (2/63) and 7.1% (2/28), respectively. This is the first study to report the frequency of JAK2 V617F and MPL W515L/K mutations in Korean patients with ET/post-ET MF. (Korean J Lab Med 2010;30:474-6)
Abstract
JAK2 V617F and MPL W515L/K mutations have been reported in approximately 50% and 5% of the patients with essential thrombocythemia (ET), respectively. We investigated the frequency of MPL W515L/K mutations in a series of consecutive patients with ET and post-essential thrombocythemia myelofibrosis (post-ET MF). The study subjects were 63 patients diagnosed either with ET (N=59) or post-ET MF (N=4) at our institution between June 2006 and February 2010. Among them, 35 (55.6%) had the JAK2 V617F mutation. MPL W515L/K mutations were detected by direct sequencing analyses of exon 10, and 2 patients were found to harbor the following MPL mutations: W515L in 1 patient with ET and W515K in 1 patient with post-ET MF. Neither of the patients had the JAK2 V617F mutation. The frequencies of the MPL W515L/K and JAK2 V617F-negative mutations in our subjects with ET/post-ET MF were 3.2% (2/63) and 7.1% (2/28), respectively. This is the first study to report the frequency of JAK2 V617F and MPL W515L/K mutations in Korean patients with ET/post-ET MF. (Korean J Lab Med 2010;30:474-6)
참고문헌 (8)
- Kilpivaara O, "JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science", Leukemia, 22, pp.1813~1817 (2008)
- Kralovics R, "Genetic complexity of myeloproliferative neoplasms", Leukemia, 22, pp.1841~1848 (2008)
- Beer PA, "MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort", Blood, 112, pp.141~149 (2008)
- Pardanani AD, "MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients", Blood, 108, pp.3472~3476 (2006)
- Schnittger S, "Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis", Haematologica, 94, pp.141~144 (2009)
- Vannucchi AM, "Characteristics and clinical correlates of MPL 515W>L", K mutation in essential thrombocythemia, 2008, pp.112, 844~847
- Boyd EM, "Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis", Br J Haematol, 149, pp.250~257 (2010)
- Thiele J, "Essential thrombocythaemia. In: Swerdlow SH, Campo E, et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed", pp.48~50 (2008), IARC Press